KEY EXECUTIVE SUMMARY
Surgical aortic valve replacement (SAVR) has long been the standard treatment for patients with severe aortic regurgitation. Recent advances in dedicated transcatheter aortic valve replacement (Dedicated TAVR), featuring novel leaflet-anchoring technology specifically designed for pure aortic regurgitation, have created a new minimally invasive treatment option for carefully selected patients who are considered at high surgical risk.
Understanding Aortic Regurgitation: When the Valve "Leaks" The aortic valve functions as a one-way gate at the outlet of the left ventricle. Under normal circumstances, it
opens during ventricular contraction to allow oxygen-rich blood to flow into the aorta and closes tightly during diastole to prevent blood from flowing backward.
Aortic regurgitation (AR) occurs when the valve fails to close completely, allowing blood to leak back into the left ventricle during diastole.
During the early stages of the disease, patients often experience no obvious symptoms. Some individuals are first diagnosed after a physician detects a heart murmur during a routine physical examination, while others may notice only mild shortness of breath during brisk walking or moderate physical activity.
As regurgitation progresses, however, the left ventricle must handle both the normal forward stroke volume and the regurgitant volume returning from the aorta. Over time, this chronic volume overload causes the ventricle to enlarge progressively, while the ventricular wall gradually becomes thinner and weaker.
Eventually, patients may develop exertional dyspnea, chest discomfort, palpitations, nocturnal shortness of breath, and ultimately heart failure.
For younger patients who can tolerate open-heart surgery, surgical aortic valve replacement (SAVR)remains the gold-standard therapy. For elderly patients or those with impaired pulmonary or renal function,previous sternotomy, severe aortic calcification, or otherwise prohibitive surgical risk, medication can only reduce cardiac workload temporarily—it cannot repair the leaking valve itself.
Why Conventional TAVR Is Unsuitable for Pure Aortic Regurgitation
Conventional TAVR was originally developed for calcific aortic stenosis, where prosthetic valves rely oncalcified native leaflets and annular radial force for secure fixation.
Pure native aortic regurgitation presents a fundamentally different challenge. Native valve leaflets are usually soft and non-calcified, while the aortic annulus and root are frequently dilated. Without calcification, conventional TAVR valves lack a stable landing zone and are more prone to migration.
Historically, off-label use of conventional TAVR in pure AR has been associated with valve migration, implantation of a second valve, and persistent residual regurgitation.
Dedicated transcatheter valve systems—including JenaValve and J-Valve—address these challenges through leaflet-based anchoring mechanisms that engage the patient's native valve leaflets directly instead of relying on annular calcification.
Pre-procedural echocardiography and cardiac CT allow individualized device sizing and procedural planning while minimizing the risk of coronary obstruction and valve malposition.
Clinical Evidence and Current Expectations
Large international clinical studies, including the ALIGN-AR trial, have demonstrated procedural success rates approaching 95%, with very low rates of moderate or severe residual regurgitation.
Compared with earlier off-label use of valves designed for aortic stenosis, dedicated valve systems provide substantially improved procedural success and lower rates of valve migration.
Nevertheless, Dedicated TAVR is not appropriate for every patient. Potential risks include vascular complications, stroke, paravalvular leak, and permanent pacemaker implantation. Approximately 10–20% of patients may require permanent pacemaker implantation after the procedure.
Patients with markedly dilated aortic roots, severely damaged native valve leaflets, or advanced left ventricular dysfunction may not be suitable candidates. Careful evaluation by an experienced multidisciplinary Heart Team remains essential.
Patient Evaluation Before the Procedure
Evaluation begins with transthoracic echocardiography to assess:
Severity of aortic regurgitation
Left ventricular size
Left ventricular systolic function
When indicated, cardiac CT is performed to evaluate:
Aortic annulus
Aortic root anatomy
Coronary ostial height
Vascular access
Renal function, anemia, pulmonary function, and frailty are also assessed.
The Transcatheter Procedure Dedicated TAVR is generally performed via transfemoral access under anesthesia with fluoroscopic and echocardiographic guidance. This minimally invasive approach avoids sternotomy and cardiopulmonary bypass for appropriately selected patients.
Post-Procedural Follow-up
Routine follow-up includes ECG and transthoracic echocardiography to assess prosthetic valve position, residual regurgitation, and left ventricular reverse remodeling.
Patients should seek immediate medical attention if they experience chest pain, syncope, unilateral weakness, fever, or persistent bleeding.
Discussing Treatment Options With Your Cardiologist
Patients are encouraged to discuss three key questions during consultation:
Has my aortic regurgitation become severe, and has my left ventricular function declined?
What factors contribute to my surgical risk?
Am I an appropriate candidate for Dedicated TAVR?
Shared decision-making helps ensure that treatment is individualized according to anatomy, overall health status, and procedural risk.
IMPORTANT REGULATORY & CLINICAL NOTE
The regulatory approval status, reimbursement policy, and clinical availability of dedicated transcatheter valve systems vary among countries and institutions. Final treatment decisions should always be based on local regulations, available technology, and comprehensive evaluation by an experienced multidisciplinary Heart Team.
Conclusion
Dedicated TAVR represents a major advancement in the treatment of severe native aortic regurgitation.Rather than replacing surgical valve replacement, it expands therapeutic options for carefully selected high-risk patients through innovative leaflet-based anchoring technology and individualized treatment planning.